Illumina rises after forecasting Q4 results beat

Shares of gene sequencing solutions company Illumina ILMN.O rise as much as 3.7% to $151

Expects Q4 revenue of $1.16 billion vs. analysts' expectations of $1.10 billion, according to data compiled by LSEG

Sees Q4 adj. EPS of $1.27 to $1.30 vs. estimates of $1.21

Co introduces dataset that maps genetic changes to help accelerate drug discovery through AI, partnering with drugmakers AstraZeneca AZN.L, Merck MRK.N and Eli Lilly LLY.N

ILMN up 6.5% over the past 12 months